NAD+ vs NMN vs NR: what each is and what the human trials measured
Reviewed 18 sourcesPublished by PepVault
NR and NMN both doubled blood NAD+ in the one head-to-head trial; injected NAD+ is the least measured. 13 human trials per form, with what each changed.

- Last reviewed
- Sources
- 18
- Questions
- 5
- Compounds
- 3
The short answer
NR and NMN both raise blood NAD+, and in the one head-to-head trial they tied: about double in 14 days at 1,000 mg a day, while plain nicotinamide did not raise it. NMN has more small wins, such as muscle insulin sensitivity up 25%; NR has the bigger trials, mostly flat. Injected NAD+ is the least measured: a 6-hour drip left plasma NAD+ flat for two hours before it rose.
Evidence: Randomized trials in people for NR and NMN (blood NAD+ is consistent; outcome trials are small, short and mixed, and one 410-person NR trial was negative); for injected NAD+, one 8-person blood-level study and small IV trials in heart patients.

What are NAD+, NMN and NR?
NAD+ (nicotinamide adenine dinucleotide) is the coenzyme every cell uses to pass electrons along while it turns food into energy. It is also the fuel that two families of repair enzymes burn: sirtuins, which switch genes on and off under stress, and PARPs, which patch damaged DNA. That is why it sits at the centre of the longevity field.
NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are precursors: smaller molecules the body builds into NAD+. Both are forms of vitamin B3. NR is two steps from NAD+; the cell adds a phosphate to make NMN, then joins NMN to the adenine half to finish the job. NMN is one step away. Nicotinamide, the plain B3 form, is a third precursor.
The most surprising recent finding is about the route. In the 2026 head-to-head trial, the team then grew human gut bacteria in the lab and found they turn NR and NMN into nicotinic acid, another B3 form, and that nicotinic acid raised NAD+ in blood samples far better than NR or NMN themselves1. Their model: a good part of what an NR or NMN capsule does may run through your gut bacteria first.

Lab note: the gut-bacteria and blood-sample results were made outside the body, in human samples; the route they suggest has not yet been traced inside people1.

Which one raises NAD+ the most?
At equal daily amounts, NR and NMN tie. Christen and colleagues gave 65 healthy adults 1,000 mg of NR, 1,000 mg of NMN, 500 mg of nicotinamide or a placebo for 14 days. Whole-blood NAD+ roughly doubled on NR and on NMN, 49.4 and 43.1 micromolar above placebo, a difference the paper calls comparable. Nicotinamide did not raise it1. The trial was open-label and run by Nestlé Research.
Within each form, more goes further. On NR, 100, 300 and 1,000 mg a day raised whole-blood NAD+ by 22%, 51% and 142% within two weeks in 140 overweight adults, and the rise held for the full 8 weeks2. On NMN, 80 middle-aged adults on 300, 600 or 900 mg a day went from about 8 to 12 nanomoles per litre at the start to 33, 45 and 49 by day 60, with the 600 and 900 mg groups close together11. A pharmaceutical-grade NMN at 1,000 mg once or twice daily raised blood NAD more at the higher amount over 14 days in 32 adults aged 55 to 8012.
Blood is not muscle. NR at 1 g a day for 21 days raised the NAD+ metabolome in the muscle of 12 older men5, but in prediabetic women, 10 weeks of NMN raised NAD+ in blood cells while muscle NAD+ itself did not change8. What a blood number does and does not tell you is the subject of our guide on NAD+ blood tests.
What did each form change besides the blood number?
The trials per form, with who took part, the daily amount, what happened to NAD+ and the outcome the trial was built to measure.
| Form | Trial | Who, how long | Daily amount | NAD+ | Outcome |
|---|---|---|---|---|---|
| NR vs NMN vs nicotinamide | Christen 20261 | 65 healthy adults, 14 days | 1,000 / 1,000 / 500 mg | About double on NR and NMN; no rise on nicotinamide | NAD+ was the outcome |
| NR | Conze 20192 | 140 overweight adults, 8 weeks | 100, 300, 1,000 mg | +22%, +51%, +142% | No flushing; side effects like placebo |
| NR | Martens 20183 | 30 middle-aged and older adults, 6 weeks each arm | 500 mg twice | About +60% in blood cells | Well tolerated; blood pressure and artery stiffness flagged for bigger trials |
| NR | Dollerup 20184 | 40 obese men, 12 weeks | 1,000 mg twice | Not the endpoint | No change in insulin sensitivity or body composition |
| NR | NICE, McDermott 20246 | 90 people with leg-artery disease, 6 months | 1,000 mg | Not the endpoint | 6-minute walk +7.0 m vs -10.6 m on placebo |
| NR | NOPARK, Brakedal 20267 | 410 people with early Parkinson disease, 52 weeks | 500 mg twice | Not the endpoint | Symptom score 2.72 points worse than placebo |
| NMN | Yoshino 20218 | 25 prediabetic women past menopause, 10 weeks | 250 mg | Up in blood cells; muscle unchanged | Muscle insulin sensitivity +25% |
| NMN | Liao 20219 | 48 amateur runners in training, 6 weeks | 300, 600, 1,200 mg | Not the endpoint | Power at the ventilatory thresholds up at 600 and 1,200 mg; VO2max unchanged |
| NMN | Igarashi 202210 | 42 healthy older men, 12 weeks | 250 mg | Whole-blood NAD+ up | Nominal gains in gait speed and left-hand grip |
| NMN | Yi 202311 | 80 healthy middle-aged adults, 60 days | 300, 600, 900 mg | From 8-12 to 33-49 nmol/L | 6-minute walk 290 to 435 m on 600 mg vs 325 to 330 m on placebo; HOMA-IR unchanged |
| NMN | Chen 2024, pooled13 | 8 trials, 342 adults, 14 days to 12 weeks | 250-2,000 mg | Not pooled | No benefit on blood sugar, insulin, HbA1c or blood fats |
| NAD+ IV | Grant 201914 | 11 healthy men, 8 given NAD+, one 6-hour drip | 750 mg | Plasma flat for 2 hours, about 4 times baseline at 6 hours | No adverse events during the drip |
| NAD+ IV | Yu 202615 | 180 adults with ischemic heart failure, 7 days | 10 mg | Not measured | Ejection fraction 45.4% vs 42.4% at 1 month |

The case for NMN is a run of small positive trials. The prediabetes result matters most: a 25% gain in muscle insulin sensitivity, which the authors compare to what about 10% weight loss does8. The runners gained power at their training thresholds9, and the 60-day trial reported a 145-metre gain on the walk test at 600 mg11. That last trial is the most striking, and it was funded by Abinopharm and Aba Chemicals, the two companies behind its NMN; three of its authors work for them, as the paper declares. Pooled, NMN has not moved blood sugar or blood fats in mostly healthy adults13.
The case for NR rests on the biggest and longest trials, and they mostly came back flat. No insulin gain at 2,000 mg a day4. A modest walking gain in leg-artery disease, which the authors say needs a larger trial6. And the biggest trial in this table, 410 people over a year, published in JAMA on Nov 17, 2026, found Parkinson symptoms rose slightly more on NR than on placebo, while serious adverse events were fewer (8.3% vs 14.1%)7. So the winner depends on the question: for raising blood NAD+, a tie; for positive outcome trials, NMN; for size and length of evidence, NR.
What about NAD+ injections and IV drips?
Injected NAD+ is the least measured form. The first study to track blood levels through a drip gave 8 healthy men 750 mg over 6 hours, a common clinic regimen. Plasma NAD+ and its breakdown products did not change for the first 2 hours: the body cleared it as fast as it arrived. By the end of the drip, plasma NAD+ was about four times its starting level and NAD+ itself was turning up in urine14.
The two placebo-controlled IV trials we found are in heart patients at a far smaller amount, 10 mg a day for 7 days. In 180 people with heart failure, ejection fraction (the share of blood pumped out with each beat) was 3 points higher than placebo at one month15; in 120 people after a heart attack, 56.3% vs 53.4% at 30 days16. Pooled with NR across four heart-failure trials, NAD+-raising treatments did not significantly improve heart function or hospital admissions, and creatinine, a kidney marker, rose slightly on IV NAD+17. A 2026 review of IV NAD+ for wellness found mostly small uncontrolled studies and case reports18. We found no controlled trial of NAD+ injected under the skin.
If you are weighing the mixing and timing of a NAD+ vial, our guide on mixing NAD+ covers it.
Commonly reported: with injected or IV NAD+, flushing, nausea, cramping and chest discomfort18, which users say track how fast it goes in and ease when it is slowed; with NR and NMN capsules, little or nothing felt, and a mild lift in daytime energy for some on NMN.
When to get help Chest pain or tightness during a drip that does not ease when the infusion is slowed or stopped is a reason to get medical help that day.
How do you tell if your form is doing anything?
Blood NAD+ reached its higher level within two weeks in the NR and NMN trials and held while people kept taking it12. The outcomes that moved were measured after 30 days to 10 weeks8911. So a fair test is one form at one amount, long enough to see something you can measure.
- Keep the form and the daily amount the same for 6 to 10 weeks, the length of the outcome trials that saw a change.
- Pick one measured outcome before you start, such as a timed walk, a training power number or a fasting glucose, and compare it at the end.
PepVault logs NR, NMN or NAD+ as part of your protocol, with a daily reminder, so a missed week shows on the calendar instead of in your results. Set reminders in PepVault
Note flushing, nausea or sleep changes in the side-effect log on the day they happen, so they sit beside that day's dose. Log it in PepVault
Sources
- Christen S et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026. PubMed 41540253
- Conze D et al. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep. 2019. PubMed 31278280
- Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018. PubMed 29599478
- Dollerup OL et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018. PubMed 29992272
- Elhassan YS et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 2019. PubMed 31412242
- McDermott MM et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun. 2024. PubMed 38871717
- Brakedal B et al. Nicotinamide riboside for patients with early-stage Parkinson disease: the NOPARK randomized clinical trial. JAMA. 2026. PubMed 42848371
- Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. PubMed 33888596
- Liao B et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr. 2021. PubMed 34238308
- Igarashi M et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging. 2022. PubMed 35927255
- Yi L et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023. PubMed 36482258
- Pencina KM et al. MIB-626, an oral formulation of a microcrystalline unique polymorph of β-nicotinamide mononucleotide, increases circulating nicotinamide adenine dinucleotide and its metabolome in middle-aged and older adults. J Gerontol A Biol Sci Med Sci. 2023. PubMed 35182418
- Chen F et al. Effects of nicotinamide mononucleotide on glucose and lipid metabolism in adults: a systematic review and meta-analysis of randomised controlled trials. Curr Diab Rep. 2024. PubMed 39531138
- Grant R et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci. 2019. PubMed 31572171
- Yu X et al. Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: a randomized, placebo-controlled trial. Am J Cardiovasc Drugs. 2026. PubMed 40954388
- Yu X et al. Effect of intravenous nicotinamide adenine dinucleotide on left ventricular function after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: a randomized controlled trial. Am J Cardiovasc Drugs. 2026. PubMed 42961639
- Hamzah KA et al. Impact of exogenous nicotinamide adenine dinucleotide and its precursors supplementation in adults with heart failure: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2026. PubMed 43040090
- Alangari A et al. Narrative review of intravenous NAD+ and NAD+ precursors in wellness and translational medicine. Front Aging. 2026. PubMed 42787547
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.